Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION To drop a secondary sits with pediatric-plan strategist because a pediatric ethicist objecting to the proposed design hit a 505(b)(2) program relying on literature plus a bridging study. Evidence is inspection-readiness findings at a CMO; write the Pharma & Life Sciences Clinical and Evidence Strategy option that extract can carry.

DECISION Pediatric-plan strategist in a 505(b)(2) program relying on literature plus a bridging study must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using inspection-readiness findings at a CMO after a pediatric ethicist objecting to the proposed design.

HYPOTHESES TO TEST 1. Pediatric-plan strategist can defend Proceed under protocol from inspection-readiness findings at a CMO after a pediatric ethicist objecting to the proposed design in a Pharma & Life Sciences challenge. 2. Pediatric-plan strategist cannot defend Proceed under protocol from inspection-readiness findings at a CMO; Pause the pathway is what the extract actually supports after a pediatric ethicist objecting to the proposed design. 3. A pediatric ethicist objecting to the proposed design never reached the population in inspection-readiness findings at a CMO — reopen intake, do not close to drop a secondary. 4. Two facts in inspection-readiness findings at a CMO after a pediatric ethicist objecting to the proposed design conflict for pediatric-plan strategist; hold this Clinical and Evidence Strategy file.

ANALYSIS REQUIRED 1. Trace CMC, labeling, or pharmacovigilance facts in inspection-readiness findings at a CMO after a pediatric ethicist objecting to the proposed design. 2. Separate an isolated adverse event from a systemic quality issue. 3. Test a protocol deviation versus a safety signal versus a filing gap on to drop a secondary. 4. For this Pharma & Life Sciences Clinical and Evidence Strategy file, read inspection-readiness findings at a CMO against a pediatric ethicist objecting to the proposed design and write the one fact that would move to drop a secondary for pediatric-plan strategist.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (inspection-readiness findings at a CMO after a pediatric ethicist objecting to the proposed design). If inspection-readiness findings at a CMO cannot force a Pharma & Life Sciences label under Clinical and Evidence Strategy, stop. Do not invent pages a 505(b)(2) program relying on literature plus a bridging study does not have.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to drop a secondary, then the evidence in inspection-readiness findings at a CMO, then the action for pediatric-plan strategist - Hypothesis scorecard against inspection-readiness findings at a CMO: supported / rejected / untestable - Named option among Proceed under protocol, Pause the pathway, Escalate safety review and the fact that kills the others - Owner and next date for pediatric-plan strategist in a 505(b)(2) program relying on literature plus a bridging study